The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: vascular disorder gene therapies. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Vascular disorder gene therapies is a key innovation area in cell & gene therapy
Vascular disorder gene therapies refer to the use of gene therapies to treat vascular disorders. These therapies involve modifying the genetic makeup of a patient’s cell to improve their ability to produce necessary proteins and alleviate symptoms of their disorder.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of vascular disorder gene therapies.
Key players in vascular disorder gene therapies – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to vascular disorder gene therapies
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| Curevac | 52 | Unlock Company Profile |
| BioMarin Pharmaceutical | 48 | Unlock Company Profile |
| Voyager Therapeutics | 44 | Unlock Company Profile |
| Sangamo Therapeutics | 40 | Unlock Company Profile |
| F. Hoffmann-La Roche | 39 | Unlock Company Profile |
| CRISPR Therapeutics | 38 | Unlock Company Profile |
| Johnson & Johnson | 35 | Unlock Company Profile |
| AGC | 33 | Unlock Company Profile |
| Children's Hospital of Philadelphia | 32 | Unlock Company Profile |
| Mayo Clinic | 23 | Unlock Company Profile |
| Assistance Publique - Hopitaux de Paris | 22 | Unlock Company Profile |
| Sanofi | 17 | Unlock Company Profile |
| St. Jude Children’s Research Hospital | 16 | Unlock Company Profile |
| Merck | 15 | Unlock Company Profile |
| Memorial Sloan Kettering Cancer Center | 14 | Unlock Company Profile |
| CARsgen Therapeutics | 12 | Unlock Company Profile |
| APEIRON Biologics | 11 | Unlock Company Profile |
| Vascular BioSciences | 10 | Unlock Company Profile |
| Ferring | 8 | Unlock Company Profile |
| Silence Therapeutics | 8 | Unlock Company Profile |
| SynPhaGen | 7 | Unlock Company Profile |
| Etubics | 6 | Unlock Company Profile |
| PT Soho Global Health | 6 | Unlock Company Profile |
| Vertex Pharmaceuticals | 5 | Unlock Company Profile |
| Nanjing Sinogen Biotech & Pharmaceutical | 5 | Unlock Company Profile |
| bluebird bio | 4 | Unlock Company Profile |
| MolMed | 4 | Unlock Company Profile |
| Seattle Children's Hospital | 3 | Unlock Company Profile |
| Children's Medical Center | 2 | Unlock Company Profile |
| Guangzhou Huazhen Pharmaceutical | 2 | Unlock Company Profile |
| Turnstone | 1 | Unlock Company Profile |
| Atugen | 1 | Unlock Company Profile |
| Kanglin Biotech Hangzhou | 1 | Unlock Company Profile |
| Obschestvo S Ogranichennoi Otvetstvennostyu Ntpharma | 1 | Unlock Company Profile |
| Jiachen Xihai (Hangzhou) Biotechnology | 1 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Curevac is one of the leading patent filers in vascular disorder gene therapies. Curevac is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna, and Cvsqiv. Curevac’s mRNA-based prophylactic vaccine candidates comprise cv7202 and cv8102. The company also carries out research and development. Its lead oncology candidate, Cv8102, is designed to modulate the tumor microenvironment. BioMarin Pharmaceutical and Voyager Therapeutics are some of the other key patent filers in vascular disorder gene therapies.
In terms of application diversity, APEIRON Biologics leads the pack, while PT Soho Global Health and Johnson & Johnson stood in the second and third positions, respectively. By means of geographic reach, Curevac held the top position, followed by BioMarin Pharmaceutical and CRISPR Therapeutics.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
